Shares in Eli Lilly rose sharply in pre-market trading today after the company reported the first phase 3 results for orforglipron, a GLP-1 agonist that it hopes will offer an oral alternative to ...

At the moment, the obesity market is pretty much a duopoly dominated by Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) and Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide), which are both ...